Ligand Pharmaceuticals LGND Non Cash Change In Estimated Fair Value Of Contingent Value Rights
Non Cash Change In Estimated Fair Value Of Contingent Value Rights at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's non cash change in estimated fair value of contingent value rights.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's non cash change in estimated fair value of contingent value rights?
- Ligand Pharmaceuticals (LGND) reported non cash change in estimated fair value of contingent value rights of -$624K in Q1 2026.
- How has Ligand Pharmaceuticals's non cash change in estimated fair value of contingent value rights changed year-over-year?
- Ligand Pharmaceuticals's non cash change in estimated fair value of contingent value rights increased by 66.8% year-over-year, from -$1.88M to -$624K.
- What does non cash change in estimated fair value of contingent value rights mean?
- This metric represents the non-cash adjustment to net income resulting from changes in the estimated fair value of contingent value rights (CVRs) issued by the company. It reflects the volatility in liabilities tied to future performance milestones or specific corporate events. Investors use this to isolate operational cash flow from accounting fluctuations in long-term contingent obligations.